adrenergic blocking

Palatrigine (BW-A 256C) is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties.

Monatepil 2maleate is an orally active Ca2+-channel antagonist and ACAT inhibitor with alpha(1)-adrenergic receptor blocking activity and antiarrhythmic properties that inhibit vasoconstriction.Monatepil 2maleate may be used to study atherosclerosis.

(S)-(-)-Atenolol has beta-adrenergic blocking effects.

Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

Quinidine hydrochloride monohydrate is an optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. It prolongs cellular action potential and decreases automaticity. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.

Yohimbine hydrochloride (Antagonil) is a plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.

Dibenamine hydrochloride is a competitive and irreversible blocker of the β-adrenergic receptor.

Bucumolol (Bucumarol) is a β-adrenergic blocking agent and a local anesthetic with antihypertensive activity and can be used to study myocardial infarction.

Emedastine (LY188695) is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition, emedastine may also inhibit the late-phase allergic reaction mediated through leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva. Emedastine does not affect adrenergic, dopamine, or serotonin receptors.

Moxisylyte hydrochloride (Thymoxamine hydrochloride) is an alpha-adrenergic blocking agent that is used in Raynaud's disease.

Guanoclor (VATENSOL) (INN), also known as guanochlor, is a sympatholytic drug. It is known to bind to non-adrenergic sites in pig kidney membranes.

Labetalone hydrochloride is an orally effective adrenergic receptor blocking drug that competitively antagonizes both α and β receptor sites.

Metipranolol (Betamann) is a type of β- Adrenergic receptors（ β- A potent antagonist of adrenergic receptor on guinea pig atria β 1- Adrenergic receptors and rat uterus β The 2-adrenergic receptor exhibited the beta blocking potentials (pA2) of 8.3 and 8.4, respectively. It is also a potent substituent in the 3H DHA binding assay, with a ligand concentration of 0.7 nM and a Ki of 39 ± 24 nM.

Chlorprothixene hydrochloride (Truxal hydrochloride) brings strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. Chlorprothixene hydrochloride s a typical antipsychotic drug of the thioxanthene (tricyclic) class.

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and no intrinsic sympathomimetic activity.

Carvedilol (SKF 105517) Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity. The S enantiomer of carvedilol nonselectively binds to and blocks beta-adrenergic receptors, thereby exerting negative inotropic and chronotropic effects, and leading to a reduction in cardiac output. In addition, both enantiomers of carvedilol bind to and block alpha 1-adrenergic receptors, thereby causing vasodilation and reducing peripheral vascular resistance.

Bometolol Hydrochloride, a beta-adrenergic blocking compound, is used for the treatment of cardiovascular disease.

Ancarolol is a blocking agent of beta-adrenergic.

Metipranolol hydrochloride is a non-selective β-adrenergic receptor blocking agent.

Corynanthe is a plant alkaloid. Corynanthe also has an alpha-2-adrenergic blocking activity.

Mafoprazine, a phenylpiperazine derivative, exhibits varying affinities for neuronal receptors, primarily exerting its antipsychotic effects through blocking D2 receptors and enhancing α-adrenergic activity. It also increases the activity of dopamine metabolites.

L-654284 is an α2-adrenergic receptor antagonist characterized by its notable selectivity. It competes with 3H-clonidine and 3H-rauwolscine for binding in vitro, exhibiting Ki values of 0.8 nM and 1.1 nM, respectively. L-654284 effectively blocks the pre-ejaculatory effects of clonidine in isolated rat vas deferens, with a pA2 value of 9.1. The compound demonstrates significant selectivity for α2 over α1 adrenergic receptors, with a Ki value of 110 nM against 3H-prazosin binding. In vivo, L-654284 significantly increases the turnover of norepinephrine in the rat cerebral cortex, indicating its activity in blocking α2-adrenergic receptors within the central nervous system.

Butocrolol is an amino alcohol derivative characterized by its β-adrenergic blocking, antiarrhythmic, and local anesthetic properties. Its efficacy in sympathetic blockade and antiarrhythmic effects is similar to propranolol, although it exhibits lower local anesthetic activity.

Tolboxane is an alpha-adrenergic blocking drug.